Surgical-pharmacological interactions in the treatment of acromegaly

References

• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189–3202.
   PubMed Web of Science ®Google Scholar
• Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7:257–266.
   PubMed Web of Science ®Google Scholar
• Gadelha M, Kasuki L, Lim D, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2018, published ahead of print.
   PubMedGoogle Scholar
• Mercado M, Gonzalez B, Vargas G, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99:4438–4446.
   PubMed Web of Science ®Google Scholar
• Guinto G, Abdo M, Zepeda E, et al. Acromegaly: role of surgery in the therapeutic armamentarium. Int J Endocrinol. 2012;2012:306094.
   PubMedGoogle Scholar
• Espinosa E, Ramirez C, Mercado M. The multimodal treatment of acromegaly: current status and future perspectives. Endocr Metab Immune Disord Drug Targets. 2014;14:169–181.
   PubMed Web of Science ®Google Scholar
• Mercado M, Espinosa E, Ramirez C. Current status and future directions of pharmacological therapy for acromegaly. Minerva Endocrinol. 2016;41(3):351–365.
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509–1517.
   PubMed Web of Science ®Google Scholar
• Lissett CA, Peacey SR, Laing I, et al. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol. 1998;49:653–657.
   PubMed Web of Science ®Google Scholar
• Wang YY, Higham C, Kearney T, et al. Acromegaly surgery in Manchester revisited–the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin Endocrinol. 2012;76:399–406.
   PubMed Web of Science ®Google Scholar
• Christy NP. Choosing the best treatment for acromegaly. JAMA. 1982;247:1320.
   PubMed Web of Science ®Google Scholar
• Tindall GT, Oyesiku NM, Watts NB, et al. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg. 1993;78:205–215.
   PubMed Web of Science ®Google Scholar
• Abosch A, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998;83:3411–3418.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526–529.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141–3148.
   PubMed Web of Science ®Google Scholar
• Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419–3426.
   PubMed Web of Science ®Google Scholar
• Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol. 2005;152:379–387.
   PubMed Web of Science ®Google Scholar
• Espinosa de los Monteros A, Sosa E, Cheng S, et al. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol. 2006;64:245–249.
   PubMed Web of Science ®Google Scholar
• Beauregard C, Truong U, Hardy J, et al. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol. 2003;58:86–91.
   PubMed Web of Science ®Google Scholar
• Nishiaka H, Fukuhara N, Horiguchi K, et al. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes. J Neurosurg. 2014;121:505–510.
   PubMedGoogle Scholar
• Hazer DB, Isik S, Berker D, et al. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg. 2013;119:1467–1477.
   PubMed Web of Science ®Google Scholar
• Anik I, Cabuk B, Gokbel A, et al. Endoscopic transsphenoidal approach for acromegaly with remission rates in 401 patients: 2010 consensus criteria. World Neurosurg. 2017;108:278–290.
   PubMed Web of Science ®Google Scholar
• Starke RM, Raper DM, Paune SC, et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013;98:3190–3198.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Rajaratnam S, Chacko G, et al. Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly. Clin Neurol Neurosurg. 2014;126:190–195.
   PubMed Web of Science ®Google Scholar
• Fathalla H, Cusimano MD, Di Leva A, et al. Endoscopic versus microscopic approach for surgical treatment of acromegaly. Neurosurgery. 2015;38:541–548.
   Google Scholar
• Mortini P, Barzaghi LR, Albano L, et al. Microsurgical therapy of pituitary adenomas. Endocrine. 2018;59:72–81.
   PubMed Web of Science ®Google Scholar
• Anik I, Cabuk B, Gakbel A, et al. Endoscopic transsphenoidal approach for acromegaly with remission rates in 401 patients. World Neurosurg. 2017;108:278–290.
   PubMed Web of Science ®Google Scholar
• Taghuci M, Sachehosseini SM, Ardakani JB, et al. Endoscopic transsphenoidal approach to the growth hormone-secreting adenomas: endocrinological outcome in 68 patients. World Neurosurg. 2018;117:e259–e368.
   PubMed Web of Science ®Google Scholar
• Phan K, Xu J, Reddy R, et al. Endoscopic endonasal versus microsurgical transsphenoidal surgery approach for growth hormone-secreting pituitary adenomas-systematic review and meta-analysis. World Neurosurg. 2017;97:398–406.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer SM. The surgical treatment of acromegaly. Pituitary. 2017;20:76–83.
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012;15:71–83.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Ironside N, Pomeraniec IJ, et al. Microsurgical versus endoscopic transshphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir. 2017;159:2193–2307.
   PubMed Web of Science ®Google Scholar
• Espinosa de los Monteros AL, Gonzalez B, Vargas G, et al. Surgical reintervention in acromegaly: is it still worth trying? Endocr Pract. 2009;15:431–437.
   PubMed Web of Science ®Google Scholar
• Wilson TJ, McKean EL, Barkan A, et al. Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications. Pituitary. 2013;16:459–464.
   PubMed Web of Science ®Google Scholar
• Antunes X, Ventura N, Carrillo GB, et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine. 2018;60:415–422.
   PubMed Web of Science ®Google Scholar
• Costa AC, Rossi A, Martinelli CE Jr, et al. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab. 2002;87:3142–3147.
   PubMed Web of Science ®Google Scholar
• Espinosa de los Monteros AL, Mercado M, Sosa E, et al. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly. J Neurosurg. 2002;97:287–292.
   PubMed Web of Science ®Google Scholar
• Alexopolou O, Bex M, Abs R, et al. Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab. 2008;93:1324–1330.
   PubMed Web of Science ®Google Scholar
• Yamada T, Soll AH, Park J, et al. Autonomic regulation of somatostatin release: studies of primary cultures of canine fundic mucosal cells. Am J Physiol. 1984;247:G567–G73.
   PubMedGoogle Scholar
• Zingg HH, Patel YC. Processing of somatostatin precursors: evidence for enzymatic cleavage by hypothalamic extract. Biochem Biophys Res Commun. 1980;93:1274–1279.
   PubMed Web of Science ®Google Scholar
• Gorden P, Comi RJ, Maton PN, et al. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989;110:35–50.
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995;16:427–442.
   PubMed Web of Science ®Google Scholar
• Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest. 1997;20:348–367.
   PubMed Web of Science ®Google Scholar
• Tulippano G, Schulz S. Novel insights in somatostatin receptor physiology. Eur J Endocrinol. 2007;156(4):543.
   Google Scholar
• Pfeiffer M, Koch T, Schröder H, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2a. J Biol Chem. 2001;276:14027–14036.
   PubMed Web of Science ®Google Scholar
• Pfeiffer M, Koch T, Schröder H, et al. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem. 2002;277:19762–19772.
   PubMed Web of Science ®Google Scholar
• Chiodini PG, Cozzi R, Dallabonzana D, et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab. 1987;64:447–453.
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med. 1996;334:246–254.
   PubMed Web of Science ®Google Scholar
• Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab. 1993;76:721–727.
   PubMed Web of Science ®Google Scholar
• Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab. 2000;85:781–792.
   PubMed Web of Science ®Google Scholar
• Van der Hoek J, Lamberts SW, Hofland LJ. Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol. 2007;156:S45–S51.
   PubMed Web of Science ®Google Scholar
• Petersen H, Bizec JC, Schuetz H, et al. Pharmacokinetic and technical comparison of Sandostatin® LAR® and other formulations of long-acting octreotide. BMC Res Notes. 2011;4:344–345.
   PubMedGoogle Scholar
• Troconiz IF, Cendros JM, Peraire C, et al. Pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet. 2009;48:51–62.
   PubMed Web of Science ®Google Scholar
• Andries M, Glintboorg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol. 2008;68:473–480.
   PubMed Web of Science ®Google Scholar
• Tutuncu Y, Berker D, Serhat I, et al. Comparison of octreotide LAR and lanreotide autogel as postoperative medical treatment in acromegaly. Pituitary. 2012;15:398–404.
   PubMed Web of Science ®Google Scholar
• Salvatori R, Woodmansee WW, Molitch M, et al. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary. 2014;17:13–21.
   PubMed Web of Science ®Google Scholar
• Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13:8–28.
   PubMed Web of Science ®Google Scholar
• Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endorcrinol. 1998;48:311–316.
   PubMed Web of Science ®Google Scholar
• Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87:99–104.
   PubMed Web of Science ®Google Scholar
• Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 2002;87:4554–4563.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol. 2006;64:342–351.
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88:3090–3098.
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397–1403.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006;91:2112–2118.
   PubMed Web of Science ®Google Scholar
• Chanson P, Borson Chazot F, Kuhn JM, et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol. 2008;69:299–305.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;94:3746–3756.
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, et al. prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol. 2007;66:859–868.
   PubMed Web of Science ®Google Scholar
• Espinosa de los Monteros AL, Gonzalez B, Vargas G, et al. Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center. Pituitary. 2015;18:290–296.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLOS One. 2012;7:336411.
   Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99:791–799.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875–884.
   PubMed Web of Science ®Google Scholar
• Samson SL. Pasireotide in acromegaly: an overview of current mechanistic and clinical data. Neuroendocrinology. 2015;102:8–17.
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98:3446–3453.
   PubMed Web of Science ®Google Scholar
• Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol. 2009;70:757–768.
   PubMed Web of Science ®Google Scholar
• Karaka Z, Tanriverdi F, Elbuken G, et al. Comparison of primary octreotide-Lar and surgical treatment in newly diagnosed patients with acromegaly. Clin Endocrinol. 2011;75:678–684.
   PubMed Web of Science ®Google Scholar
• Abu Dabrh AM, Mohammed K, Asi N, et al. Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99:4003–4014.
   PubMed Web of Science ®Google Scholar
• Ramirez C, Vargas G, Gonzalez B, et al. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol. 2012;166:21–26.
   PubMed Web of Science ®Google Scholar
• Vilar L, Fleseriu M, Navez LA, et al. Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. Endocrine. 2014;46:577–584.
   PubMed Web of Science ®Google Scholar
• Pita-Gutierrez F, Peterga-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLOS One. 2013;8:e61523.
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow up results of transsphenoidal surgery in19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab. 1999;84:351–355.
   Web of Science ®Google Scholar
• Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93:2984–2990.
   PubMed Web of Science ®Google Scholar
• Fougner SL, Bollerslev J, Svartberg J, et al. Preoperative octreotide treatment of acrmegaly: long-term results of a randomized controlled trial. Eur J Endocrinol. 2014;171:229–335.
   PubMed Web of Science ®Google Scholar
• Mao ZG, Zhu YH, Tang HL, et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol. 2010;162:661–666.
   PubMed Web of Science ®Google Scholar
• Shen M, Shou X, Wang Y, et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J. 2010;57:1035–1044.
   PubMed Web of Science ®Google Scholar
• Duan L, Zhu H, Xing B, et al. Prolonged preoperative treatment of acromegaly with somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1–3): a retrospective cohort study conducted at a single center. BMC Endocr Disord. 2017;17:55.
   PubMed Web of Science ®Google Scholar
• Petrossians P, Borges-Martins L, Espinosa C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005;152:61–66.
   PubMed Web of Science ®Google Scholar
• Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006;91:85–92.
   PubMed Web of Science ®Google Scholar
• Jallad RS, Musolino NR, Kodaira S, et al. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol. 2007;67:310–315.
   PubMed Web of Science ®Google Scholar
• Casanueva FF, Barkan AL, Buchfelder M, et al. Criteria for the defintion of Pituitary Tumor Centers of Excellence (PTCOE): a pituitary society statement. Pituitary. 2017;20:489–498.
   PubMed Web of Science ®Google Scholar